**Genomic Applications Partnership Program**

Expression of Interest

**GENERAL INSTRUCTIONS**

***Please delete this page before submitting the Expression of Interest (EOI).***

**All GAPP Expressions of Interest (EOIs) must be submitted to Genome Canada through a regional Genome Centre. Please contact your regional Genome Centre to discuss your submission.**

Each EOI submission must include:

* One (1) electronic copy of the EOI in PDF format. The file should be labelled using the surnames of the Academic and Receptor Project Leaders (format: Smith, Johnson).
* One (1) electronic copy of the signature pages of the EOI, completed and signed by ALL parties indicated. Electronic signatures are acceptable.

The signatures of the Project Leader(s) confirm that all members of the Project team have reviewed and approve the submission of the EOI to the Genome Centre(s) and Genome Canada. The signature(s) of the authorized representative(s) of the Academic Institution, Receptor Organization and the Genome Centre(s) confirm that these parties have reviewed and approve the submission of the EOI to Genome Canada. It is expected that the EOI has been approved by both the program and financial representatives of the Genome Centre(s).

Type must be single-spaced, with top and bottom margins of a minimum of 1.7 cm and left and right margins of a minimum of 2.5 cm. Type font Calibri font 11 points must be used.

The Investment Strategy and Guidelines are provided in both official languages. However, to ensure that EOIs can be evaluated by the most appropriate, independent reviewers, all applications must be submitted in English.

Please refer to the [Genomic Applications Partnership Program (GAPP) Investment Strategy and Guidelines](http://www.genomecanada.ca/en/portfolio/research/genomic-applications-partnership-program.aspx) for more details on the program.

**Genomic Applications Partnership Program**

Expression of Interest

**Project Title:**

**Estimated Total Budget:**

**Amount Requested from Genome Canada (max 1/3 of Total Budget):**

**Project Start and End Dates (month/year to month/year):**

|  |  |  |
| --- | --- | --- |
| **Academic Project Leader**[[1]](#footnote-2) |  | **Receptor Project Leader**[[2]](#footnote-3) |
| Name |  |  | Name |  |
| Position |  |  | Position |  |
| Academic affiliation (institution & dept.) |  |  | Organization |  |
|  |
| Telephone  |  |  | Telephone |  |
| E-mail |  |  | E-mail |  |
| Date |  |  | Date |  |
| Signature |  |  | Signature |  |
| **Academic Institution Officer**[[3]](#footnote-4) |  | **Receptor Organization Officer**[[4]](#footnote-5) |
| Name |  |  | Name |  |
| Position |  |  | Position |  |
| Institution |  |  | Organization |  |
|  |
| Telephone  |  |  | Telephone |  |
| E-mail |  |  | E-mail |  |
| Date |  |  | Date |  |
| Signature |  |  | Signature |  |

**Genome Centre CEO(s) or authorized representative**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Administrative Genome Centre[[5]](#footnote-6) |  |  | Co-lead Centre (if applicable)[[6]](#footnote-7) |  |
| Representative Name |  | Representative Name |  |
| Position |  | Position |  |
| Date |  | Date |  |
| Signature |  | Signature |  |

**Other Receptors (if applicable)**

|  |  |
| --- | --- |
| Organization | Representative |
|  |  |
|  |  |
|  |  |

# Project Sector(s)

Indicate the areas that the proposal is targeting. If relevant to more than one area, use numbers to indicate the relative weighting (i.e. 1 = primary focus; 2 = secondary focus, etc.; do not use the same number more than once)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Agriculture |  | Energy |  | Environment |
|  |  |  |  |  |  |
|  | Fisheries  |  | Forestry |  |  |
|  |  |  |  |  |  |
|  | Human Health |  | Mining  |  |  |
|  |  |  |  |  |  |

**1. Executive Summary (maximum 1 page)**

* Briefly describe the key need or opportunity as defined by the Receptor.
* Outline your proposed genomics-derived solution and how it will impact the challenge or opportunity.
* Briefly summarize the pathway to commercialization or implementation of the innovation.
* Briefly summarize the social and/or economic benefits to Canada in the near term (within 3 to 5 years after project completion).

**2. Targeted need / opportunity (maximum 1 page)**

* Describe and quantify the need or opportunity, as defined by the Receptor, that the project’s primary innovation intends to address, including:
	+ specific users/consumers/clients/patients who will be impacted,
	+ potential market size (or cost of public service) for the innovation,
	+ shortcomings of current solutions (if any) or other basis for unmet need and/or space for a new entrant.

**3. Proposed genomics-derived solution and rationale (maximum 2 pages)**

* State the overall goal of the project (i.e., the resulting innovation and its desired performance at project completion).
* Briefly explain the major steps for achieving the project goal, including key subject matter (organisms, genes, proteins, etc.), the main scientific methods that will be used, and the deliverable of each step (with quantitative performance targets, where applicable).
* Summarize the scientific rationale for the proposed approach and expected outcomes (i.e., background R&D and other evidence, performance of existing prototype, precedence in the sector, input from end users, etc.). List key references in Appendix II.

**4. Commercialization / Implementation plan (maximum 2 pages)**

* State the value proposition of the primary innovation, with reference to alternatives and competitors (if any), describing how it will add value in its ultimate use.
* If the project targets a commercial opportunity:
	+ summarize the pathway to monetization / market / implementation (including regulation, social considerations, reimbursement and adoption, as applicable) that the Receptor will pursue,
	+ outline the business model for exploiting and sustaining the innovation in commercial use (whether or not the Receptor will be involved at that stage).
* If the project targets a public service need:
	+ describe the pathway to adoption and implementation by the Receptor and/or other key users of the innovation, including regulatory and social considerations
	+ explain how the innovation will be funded and maintained in the long term.
* State if any Intellectual Property (IP) is expected to be created or advanced through the project and describe its ownership and management by the concerned parties.

**5. Benefits to Canada (maximum 1 page)**

* Quantify the projected commercial or public service impact (e.g., revenue/savings, asset value, improved outcomes, or other relevant metrics) of the primary innovation within 3 to 5 years after project completion.
* Describe any other tangible social and/or economic benefits to Canada that are likely to result (directly or indirectly) from the commercialization / implementation of the primary innovation (see [GAPP Investment Strategy and Guidelines](http://www.genomecanada.ca/en/portfolio/research/genomic-applications-partnership-program.aspx) for details on Benefits to Canada).
* Describe the additional steps (if any) beyond the Receptor’s commercialization / implementation plan that will be required for full realization of the benefits to Canada (whether or not the Receptor will be involved at that stage).

**6. Project management and funding (maximum 1 page + Appendix I)**

* Provide a brief overview of the relevant credentials and experience of the Academic and Receptor project leader(s) and other key members of the project team, including examples (if any) of successful collaborative R&D and implementation projects in the relevant field.
* Explain the specific roles of each project leader and major contributor, including project leadership and oversight, contribution of specific knowledge and resources, and execution of specific project activities.
* Provide a summary of the project’s high-level budget by activity and year as well as a co-funding summary (see Appendix I).

**7. Request for Exemption from obligations under Genome Canada’s Data Release and Resource Sharing policy (maximum 1/2 page)**

* A requirement of the Supplementary (final) Proposal is a Data Release and Resource Sharing Plan that complies with Genome Canada’s [policy](https://www.genomecanada.ca/sites/default/files/publications/datareleaseandresourcesharingpolicy.pdf) for data and resources generated by funded projects. **If a partial or full exemption from this policy is being requested, describe the information and/or resources to be exempted and provide the justification for the exemption here.** If no exemption is being requested, leave this section blank.

**8. Reference to previous submission (if applicable) (maximum 2 pages)**

* If this is a resubmission of a proposal previously submitted to Genome Canada, highlight the key differences between that application and the current proposal, with reference to previous review feedback that has been addressed.

|  |
| --- |
| **Appendix I – Project budget and co-funding summary** |
| **A) Budget Summary** |  |  |  |
| This budget is an estimate only. An itemized budget will be required with the Full Proposal. |
|  |  |  |  |  |
| **Project budget (CDN$)** | **Year 1** | **Year 2** | **Year 3** | **Total / category** |
|
| Activity 1 |   |   |   |   |
| Activity 2 |   |   |   |   |
| Activity 3 |   |   |   |   |
| Activity 4 |   |   |   |   |
| Project Management |   |   |   |   |
|   |   |   |   | **Total project** |
| **Total / year** |   |   |   |   |
|  |  |  |  |  |
|  |  |  |  |  |
| **B) Co-funding summary** |  |  |  |
| Genome Canada will fund up to 1/3 of approved eligible costs for new R&D activities that are an integral part of the Genome Canada approved project. |
| The remaining 2/3 of the funding must be secured through co-funding, with at least 1/3 provided by the Receptor. |
|  |  |  |  |  |
| **Funding source** | **Type** | **Status** | **Total contribution (CDN$)** |  |
| Genome Canada |  |  |  |  |
| Organization 1 |   |   |   |  |
| Organization 2 |   |   |   |  |
|   |   |   |   |  |
|   |   |   |   |  |
| **Total** |   |  |
|  |  |  |  |  |
| (1) Type of co-funding can be: unrestricted cash, restricted cash (as specified by funder), in-kind contribution. |
| (2) Status of co-funding can be: received, committed, awaiting response, yet to apply.  |  |

**Appendix II – References**

1. The Academic Project Leader assumes the administrative and financial responsibility for the project funds that will be paid to his/her institution once an agreement is signed. [↑](#footnote-ref-2)
2. The Receptor Project Leader assumes the administrative and financial responsibility for the project expenses incurred within their organization once an agreement is signed. [↑](#footnote-ref-3)
3. The EOI must be signed by a representative of the Academic Project Leader’s host institution or organization with authority to receive and dispense the project funds. [↑](#footnote-ref-4)
4. The EOI must be signed by a representative of the Receptor organization with authority to commit the co-funding contribution, dispense funds and allocate required resources to the project. [↑](#footnote-ref-5)
5. The Administrative Centre is the Genome Centre that has the lead administratively on a project and is responsible for transferring funds to the project, project monitoring, and reporting to Genome Canada on all aspects of the project. [↑](#footnote-ref-6)
6. A Co-lead Genome Centre is appropriate if substantial project activities will take place in the regions of more than one Genome Centre and will involve participants from each region. The Co-Lead Centre is responsible to support the Lead Centre on monitoring and reporting as needed. [↑](#footnote-ref-7)